Video, enVista® IOL in Oculocutaneous Albinism Patient

In this educational video, Anil Shivaram, MD of Claremont Eye Associates implants the enVista® IOL from Bausch + Lomb in a patient with type 1 oculocutaneous albinism utilizing the Stellaris® Vision Enhancement System and Storz CapsuleGuard IA handpiece.

Related Videos

Related Content

Advertisement

October 4th 2024

Researchers: New AI model reaches clinical-expert-level accuracy in complex medical scans

September 23rd 2024

Innovation Series: What a noninvasive eye drop approach may mean for the future of keratoconus

October 3rd 2024

Aldeyra Therapeutics resubmits New Drug Application for reproxalap for the treatment of dry eye disease

August 30th 2024

Latest advances in X-linked retinitis pigmentosa: Optimizing diagnosis and developments in gene therapy

October 3rd 2024

NYU Langone receives $1.6 million grant from NIH to study Alzheimer, Parkinson progression

October 2nd 2024

Novaliq and Laboratoires Théa announce partnership and European Commission approval of ciclosporin 0.1% eye drops solution

Related Content

Advertisement

October 4th 2024

Researchers: New AI model reaches clinical-expert-level accuracy in complex medical scans

September 23rd 2024

Innovation Series: What a noninvasive eye drop approach may mean for the future of keratoconus

October 3rd 2024

Aldeyra Therapeutics resubmits New Drug Application for reproxalap for the treatment of dry eye disease

August 30th 2024

Latest advances in X-linked retinitis pigmentosa: Optimizing diagnosis and developments in gene therapy

October 3rd 2024

NYU Langone receives $1.6 million grant from NIH to study Alzheimer, Parkinson progression

October 2nd 2024

Novaliq and Laboratoires Théa announce partnership and European Commission approval of ciclosporin 0.1% eye drops solution